Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
Switch from single-tablet regimen to 3 tablets works in Denmark

Switching from an efavirenz-containing single-tablet regimen (STR) to an efavirenz containing triple-tablet regimen (TTR) to save money maintained viral suppression in Denmark. Antiretroviral-naive people who started the TTR attained the same virologic suppression rate as people who started the STR combination.

Published
10 July 2014
From
International AIDS Society
Egypt's Military Regime Still Pushing Bogus HIV, Hepatitis "Cure"

The so-called 'miracle' device originally made media headlines in February when it was slammed for its tenuous grasp of the science surrounding both life-threatening diseases.

Published
09 July 2014
From
Poz magazine news
Option B+: In obstacle courses to lifelong antiretroviral treatment, hurdles are higher for pregnant women, study says

Work conflicts, hidden HIV status, and bad treatment by staff are among the hurdles keeping women living with HIV from continuing antiretroviral treatment for life following childbirth, according to a article published last month ahead of print in the Journal of Acquired Immune Deficiency Syndromes.

Published
09 July 2014
From
Science Speaks
New tool announced to fight HIV cure hype in the media

In an effort to aid in the fight against HIV cure hype and educate media sources as well as the broader community on the current state of HIV cure research, three agencies have teamed up and published the HIV/AIDS Cure Glossary.

Published
08 July 2014
From
Project Inform
Common HIV Drug May Boost Suicide Risk

A medication commonly used to treat HIV appears to double the risk that patients will develop suicidal thoughts or take their lives, new research contends. The finding concerns the anti-HIV drug efavirenz, which is marketed as Sustiva.

Published
02 July 2014
From
Web MD
New ARV prescribing guidelines for London (2014)

The guidelines are the result of a therapeutic tender, which encourages drug manufacturers to offer volume discounts for different stages of the treatment pathway, for example, for preferred use in first-line, second-line and multiple resistant treatment.

Published
01 July 2014
From
HIV i-Base
Protease inhibitor therapy increases underlying genetic risk of diabetes for women with HIV

Treatment with an antiretroviral regimen based on a protease inhibitor magnifies any underlying genetic susceptibility to diabetes for women living with HIV, investigators report in the online edition

Published
01 July 2014
By
Michael Carter
Triumeq® (dolutegravir/abacavir/lamivudine) single-tablet regimen receives positive CHMP opinion in Europe for the treatment of HIV

ViiV Healthcare today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending marketing authorisation for Triumeq® (dolutegravir/abacavir/lamivudine) for the treatment of HIV infection in adults and adolescents aged 12 years and older and weighing at least 40kg.

Published
30 June 2014
From
Viiv Healthcare press release
Researcher Admits to HIV Vaccine Fraud

United States prosecutors have filed charges against a researcher who admitted to fraudulently reporting data while conducting research for a HIV vaccine. Dong-Pyou Han, a former laboratory manager at Iowa State University, admitted to putting human antibodies into samples of rabbit’s blood to create the illusion that an experimental vaccine was potentially effective. After millions in grants from the National Institutes of Health and years of work, another laboratory discovered irregularities that showed the results were false.

Published
26 June 2014
From
Guardian Liberty Voice
Lowering toxicity of new HIV drugs predicted to improve life expectancy

While bringing new drugs to market is important for increasing life expectancy in younger people with HIV, lowering the toxicity of those drugs may have an even greater health impact on all HIV patients, a University of Pittsburgh Graduate School of Public Health analysis reveals.

Published
26 June 2014
From
EurekAlert

Filter by country